BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 12116607)

  • 1. The controversy over estrogen replacement therapy: an update on clinical trials.
    Gnatuk CL
    Curr Womens Health Rep; 2002 Apr; 2(2):89-94. PubMed ID: 12116607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative cardiovascular effects of different progestins in menopause.
    Rosano GM; Fini M
    Int J Fertil Womens Med; 2001; 46(5):248-56. PubMed ID: 11720197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effects of SERM on breast cancer and cardiovascular disease: making a comparison between raloxifene use and hormone replacement therapy on the risks of the diseases].
    Higuchi T; Mizunuma H
    Clin Calcium; 2004 Oct; 14(10):81-4. PubMed ID: 15577136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cardiovascular effects of selective estrogen receptor modulators. Current perspectives].
    Simoncini T; Mannella P; Genazzani AR
    Recenti Prog Med; 2003 Feb; 94(2):51-6. PubMed ID: 12908369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hormonal replacement therapy and selective estrogen receptor modulators in prevention of cardiovascular disease].
    Kozakiewicz K; Wycisk A
    Wiad Lek; 2006; 59(5-6):377-82. PubMed ID: 17017486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hormone replacement therapy in peri- and postmenopause. Routine use is not indicated].
    Emons G; Westphalen S
    MMW Fortschr Med; 2002 Feb; 144(9):30-3. PubMed ID: 11921648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hormone replacement therapy and cardiovascular prevention. Where are we now?].
    Lerman J; Siseles N
    Medicina (B Aires); 2008; 68(3):251-7. PubMed ID: 18689159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preserving cardiovascular benefits of hormone replacement therapy.
    Bush TL
    J Reprod Med; 2000 Mar; 45(3 Suppl):259-73. PubMed ID: 10756507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of estrogens and selective estrogen receptor modulators on indicators of cardiovascular health in postmenopausal women.
    Klein KP; Herrington DM
    Medscape Womens Health; 2002; 7(5):2. PubMed ID: 12466731
    [No Abstract]   [Full Text] [Related]  

  • 10. Estrogens, progestins, selective estrogen receptor modulators, and the arterial tree.
    Wild RA; Reis SE
    Am J Obstet Gynecol; 2001 Apr; 184(5):1031-9. PubMed ID: 11303216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uterine effects of estrogen plus progestin therapy and raloxifene: adjudicated results from the EURALOX study.
    Neven P; Quail D; Lévrier M; Aguas F; Thé HS; De Geyter C; Glant MD; Beck H; Bosio-LeGoux B; Schmitt H; Hottgenroth A; Nickelsen T
    Obstet Gynecol; 2004 May; 103(5 Pt 1):881-91. PubMed ID: 15121561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effects of estrogen and selective estrogen receptor modulators on osteoporosis].
    Urano T
    Clin Calcium; 2005 Apr; 15(4):591-5. PubMed ID: 15802770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postmenopausal hormone replacement therapy: does the progestin make a difference?
    Fylstra DL
    J S C Med Assoc; 2002 Feb; 98(1):12-9. PubMed ID: 11859600
    [No Abstract]   [Full Text] [Related]  

  • 14. Postmenopausal hormone therapy: cardiovascular risks.
    Prescrire Int; 2003 Apr; 12(64):65-9. PubMed ID: 12674130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.
    Lee WL; Chao HT; Cheng MH; Wang PH
    Maturitas; 2008 Jun; 60(2):92-107. PubMed ID: 18534794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of the association of estrogens and progestins with cardiovascular disease in postmenopausal women.
    Psaty BM; Heckbert SR; Atkins D; Siscovick DS; Koepsell TD; Wahl PW; Longstreth WT; Weiss NS; Wagner EH; Prentice R
    Arch Intern Med; 1993 Jun; 153(12):1421-7. PubMed ID: 8512434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing raloxifene with continuous combined estrogen-progestin therapy in postmenopausal women: Review of Euralox 1.
    Neven P; Quail D; Marin F; Creatsas G; Depypere H; Rechberger T; Liu-Léage S; Pavo I; Schmitt H; Nickelsen T
    Maturitas; 2005 Oct; 52(2):87-101. PubMed ID: 15967604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Landmark hormone replacement therapy study stopped after finding more harms than benefits.
    Rollins G
    Rep Med Guidel Outcomes Res; 2002 Aug; 13(15):5-7. PubMed ID: 12553323
    [No Abstract]   [Full Text] [Related]  

  • 19. Hormone therapy and selective estrogen receptor modulators for prevention of coronary heart disease in postmenopausal women estrogen replacement from the cardiologist's perspective.
    Mobasseri S; Liebson PR; Klein LW
    Cardiol Rev; 2004; 12(6):287-98. PubMed ID: 15476565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast cancer risk with postmenopausal hormonal treatment.
    Collins JA; Blake JM; Crosignani PG
    Hum Reprod Update; 2005; 11(6):545-60. PubMed ID: 16150813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.